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Key Point: Jarid1b knockdown promotes enhanced HSC activity 
ABSTRACT 
Histone methylation is a dynamic and reversible process proposed to directly impact on stem 
cell fate. The Jumonji (JmjC) domain-containing family of demethylases comprises 27 
members which target mono-, di- and tri-methylated lysine residues of histone (or non-
histone) proteins. To evaluate their role in regulation of hematopoietic stem cell (HSC) 
behaviour we performed an in vivo RNAi-based functional screen and demonstrated that 
Jarid1b and Jhdm1f play opposing roles in regulation of HSC activity. Decrease in Jarid1b 
levels correlated with an in vitro expansion of HSCs with preserved long term in vivo 
lympho-myeloid differentiation potential. Through RNA sequencing analysis Jarid1b 
knockdown was associated with increased expression levels of several HSC regulators 
(Hoxa7, Hoxa9, Hoxa10, Hes1, Gata2) and reduced levels of differentiation associated genes. 
shRNA against Jhdmlf, in contrast, impaired hematopoietic reconstitution of bone marrow 
cells. Together, our studies identified Jarid1b as a negative, and Jhdmlf as a positive regulator 
of HSC activity.   
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INTRODUCTION 
Multipotent hematopoietic stem cells (HSCs) ensure sustained production of lineage 
committed blood cells throughout life. The pool of long-lived HSCs is preserved due to their 
inherent capacity to undergo self-renewal divisions. Cell fate decisions result from integrated 
influences of various nuclear factors, including chromatin modifiers that regulate access of 
transcriptional machinery to specified genomic loci. Chromatin, consisting of intertwined 
DNA, histone and non-histone proteins, can be covalently modified by epigenetic effectors. 
DNA methyltransferases (DNMTs) modify carbon-5 of cytosine bases within cytosine-
guanosine dinucleotides (CpG) frequently located proximal to or in promoters1. In 
mammalian cells, the mechanism and effectors of DNA demethylation are less well 
understood, but recent reports suggest this process likely requires the activity of the TET 
enzyme family2,3. Post-translational modifications of histones include methylation, 
acetylation, phosphorylation, ubiquitination, sumoylation or ADP-ribosylation (reviewed in 4) 
and introduce changes in local chromatin topography that subsequently alter gene expression 
patterns in developmental stage and cell context-specific manners. 
Methylation of histone residues represents a classical paradigm linking epigenetics to cell fate 
and identity, best illustrated by the antagonistic forces of Polycomb (PcG) and Trithorax 
(Trx) group protein complexes on regulation of key developmental loci such as Hox gene 
clusters (reviewed in5). In general, PcG protein repressor complexes PRC2 and PRC1 are 
associated with gene silencing, and Trx complexes (compass-like or MLL, Mixed Lineage 
Leukemia, complexes) with gene activation. The histone methyltransferase (HMT) Enhancer 
of Zeste Homolog 2 (EZH2) of the PRC2 complex catalyzes tri-methylation of lysine 27 on 
histone H3 (H3K27me3). This covalent mark serves as a docking site for the PRC1 complex 
which mono-ubiquitinates lysine 119 of histone H2A (H2AK119Ub) resulting in gene 
silencing.  MLL complexes counteract these epigenetic marks via tri-methylation of lysine 4 
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on histone H3 (H3K4me3) at transcription start sites, a mark associated with active gene 
transcription6 and recruitment of H3K27me3 demethylases UTX and JMJD37-9. Additional 
Trx-mediated modifications such as acetylation of H3K27 (H3K27Ac) and di-methylation of 
H3K36 (H3K36me2) further oppose the PcG mediated gene repression.  
Histone methylation status on lysine (K) or arginine (R) residues is reported to evolve 
through highly dynamic and finely regulated processes (reviewed in10). Histone demethylases 
(HDMs) integrate into multi-unit complexes resulting in removal of methylation marks by 
amine oxidation, deimination11 or hydroxylation.  The lysine specific demethylase 1 
(LSD1/KDM1A)-related HDM can demethylate mono- and di-methylated lysine residues. 
Jumonji C (JmjC) domain-containing HDMs (n=27) are capable of removing all three lysine 
methylation states by an oxidative reaction requiring α-ketoglutarate and iron (Fe2+) as 
cofactors. Like the LSD1 family,  JmjC/JARID1 proteins act as components of multi-subunit 
complexes, with non-catalytic domains proposed to mediate protein-protein interactions 
involved in regulation of demethylase activity  and/or target specificity (reviewed in12). In 
addition, JMJD6 demethylates arginine residues13, and bacterial Jumonji domain-containing 
AlkB protein is involved in DNA demethylation and repair14,15 suggesting that JmjC 
substrates include non-histone targets.  
JmjC protein activity results in dynamic chromatin landscape changes which enable 
expression of distinct gene subsets required for self-renewal 16, proliferation 17, 
differentiation18-20, cellular senescence 21 and cancer  development 22-24. In light of these 
findings, an established in vivo RNAi based screening strategy 25 was undertaken, in a 
targeted way, to assess the impact of JmjC gene down-regulation on adult primary HSC cell 
fate. We identify Jarid1b as a negative regulator of HSC self-renewal and progenitor cell 
activity, while Jhdm1f positively influences blood reconstitution. Results from these 
experiments and possible downstream functional networks involved are presented. 
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METHODS 
Construction of shRNA retroviral vectors 
For each gene target, 3-5 shRNAs were designed as single stranded oligonucleotides also 
incorporating miR-30 flanking arms using the RNAi Central shRNA design tool at 
http://cancan.cshl.edu/RNAi_central/main2.cgi and our previously established 
methodology25. 
  
Mice  
C57BL/6J (CD45.2+) transplant recipients and C57BL/6Ly-Pep3b (CD45.1+) congenic bone 
marrow donor mice were bred and manipulated in a specific pathogen-free animal facility.  
Experimental procedures were revised and approved by the University of Montreal animal 
ethics committee (Comité de Déontologie de l’Expérimentation sur les Animaux de 
l’Université de Montréal). 
 
Flow cytometry   
Negative selection of hematopoietic lineage marker (GR-1+, B220+, Ter119+) expressing cells 
(Lin-) was performed as described25. Lin- bone marrow fraction was subsequently stained 
with PE-Cy7-conjugated anti-cKit, PE-Cy5-conjugated anti-Sca1 (eBioscience), PE-
conjugated anti-CD150 (BioLegend) and FITC-conjugated anti-CD48 (BD Biosciences) 
antibodies, followed by isolation of HSC-enriched PE-Cy5-Sca1+/PE-Cy7-cKit+/PE-
CD150+/FITC-CD48-/APC-Lin- cell population. Day E14.5d.p.c. fetal liver derived HSCs 
were purified from the Lin- cell populations by isolating the fraction of PE-Cy5-Sca1+/PE-
CD11b+/PE-Cy7-CD150+/FITC-CD48-/APC-Lin- cells. Cells were sorted using the 
FACSAria cell sorter (Becton-Dickinson, San Jose, CA, USA. The frequency of LT-HSC in 
the sorted populations (Table S1), the proportions of transduced (GFP+) transplant-derived 
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(CD45.1+) peripheral blood leukocytes 26 and contribution of these cells to reconstitution of 
hematopoietic lineages 25,26 were determined as described. 
  
HSC/progenitor cell culture, retroviral infection and transplantation 
Suspension cell cultures of HSC/progenitor cell enriched populations, generation of 
retrovirus-producing GP+E-86 cells and infection of the sorted HSC/progenitor cells were 
performed as described26. For validation assays, 1500 CD150+CD48- Lin- bone marrow 
derived cells were introduced in co-culture with retroviral producers in 96-well plates26. After 
5-day incubation (day 0), the total cell content of each well was harvested, and partitioned for 
transplantation and cell culture as previously reported25. Briefly, 1/8 of cell suspension was 
transplanted into sublethally irradiated congenic recipients (n=2 for each shRNA species). 
The remaining cells were cultured for additional 7 days and proportions corresponding to 1/8 
of the cell input transplanted in 3 recipient mice (day 7). To compensate for the shJhdm1f-
associated loss of reconstituting activity, ¼ of day 0 cell suspensions was transplanted in each 
of the 3 recipients, and no continuing suspension cultures were initiated. 
   
Clonogenic progenitor cell assays  
The total numbers and distributions of myeloid clonogenic progenitors in various cell 
populations recovered from the 5-day co-culture with retroviral producers (day 0), or from 
the subsequent suspension cultures (day 5-7) were determined as described25. 
 
Microphotograpy  
Images of Wright-stained cytospin cell preparations were acquired using a Leica DMIRB 
microscope with an HCXPL FluotarL 40×/0.6 numeric aperture objective (Leica) and a 
Retiga EX-i camera (Q-Imaging). Images were transformed directly into TIFF files using 
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Adobe Photoshop Version 6.0 (Adobe Systems). In situ images of colonies in semisolid 
media were acquired using the same set up, but using the HC Pl Fluotar 10X/0.30, Ph 1 lens.  
 
Competitive repopulating unit (CRU) assay 
These assays were performed as previously described25,26. 
 
Q-RT-PCR assessment of JmjC gene expression in HSC enriched populations 
Gene expression was assessed by Q-RT-PCR using the Roche LightCycler® 480 System 
(Roche, Basel, Switzerland). Reactions were performed in 384-well plates for 50 
amplification cycles (95°C 10 s; 60°C 10 s; 72°C 10 s). Reference Taqman® gene assay 
(Hprt) was purchased from Applied Biosystems.  Primer sequences in Table S2, Delta Ct 
values in Table S3. 
 
ChIP-chip analysis 
Two-colour hybridizations on NimbleGen MM8 Deluxe Promoter HX1 arrays were carried 
out using 34μg of Cy5-labeled input and 34μg of Cy3-labeled test (shLuc or shJarid1b) ChIP 
DNA using the NimbleGen hybridization kit as recommended by the manufacturer.  Arrays 
were scanned at 5 μm resolution using a GenePix4000B scanner (Molecular Devices).  Data 
extraction and peak finding analysis was done using NimbleScan 2.5 and visualized in the 
UCSC genome browser. 
 
RNA sequencing analysis 
RNA sequencing was performed as previously described27. RNA was extracted from 1x 106 
cells for each test (sh3Jarid1b-GFP) and control (shLuc-GFP) culture condition. Cultures 
were initiated with 24,000 CD150+CD48-Lin- bone marrow cells and expanded for 4 days 
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following infection with the respective constructs. Cells from 2 independent cultures were 
isolated for each condition, and only cell populations with >90% gene transfer were selected. 
 
shRNA-mediated knockdown in NUP98-Hoxa10ΔHD-transduced HSCs 
1500 purified CD150+CD48-Lin- bone marrow cells were co-cultured with irradiated (40 Gy) 
GP+E86 cells producing MSCV-NUP98-HOXA10HD-IRES-Puromycin (NA10HD) virus. 
After 4-day co-culture, cells were collected and cultured for 6 days in the presence of 10 
μg/mL of Puromycin, harvested and stained with APC/Cy7-conjugated anti-CD43 
(BioLegend), APC-conjugated anti-Sca1, PE/Cy7-conjugated anti-Gr1 and PE/Cy5-
conjugated anti-F4/80 (eBioscience). The sorted NA10-transduced Sca1+CD43+Gr1-F4/80- 
cell subpopulation was co-cultured with GP+E86 cells producing shLuc, sh3Jarid1b or 
sh1Moz recombinant retroviruses. After 4 days, the nonadherent cells were recovered and 
expanded for additional 6 days. To assess the extent of differentiation in these cultures, cells 
were stained with PE/Cy7-conjugated anti-Gr1 and PE/Cy5-conjugated anti F4/80-PE/Cy5 
antibodies. Data were acquired using BD LSRII cytometer and FACSDiva Version 4.1 
software (BD Biosciences PharMingen), and analyzed using the FlowJo Version 7.6.4 
software (TreeStar). 
 
Statistical Analysis 
Statistical analysis was conducted using Prism (Graphpad Software version 5) or SPSS. The 
two-tailed Student-t-test was performed throughout unless otherwise stated.  Statistical 
significance was calculated at a 95% confidence level. 
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RESULTS 
JmjC gene expression in HSC-enriched populations 
Expression profiles were obtained for all JmjC genes in sorted mouse bone marrow and fetal 
liver cell populations comprising ≥30% of functionally defined long-term-repopulating LTR-
HSCs, as evaluated by competitive repopulation unit (CRU) assays 28 (Table S1). Results 
showed that all JmjC gene transcripts, except Hairless, were detected at relatively high levels 
(Fig. 1A). The histone acetyl-transferase MOZ (MYST3), reported as essential for HSC 
expansion29,30 was also highly expressed in this fraction and chosen as a control for the 
functional screen. Transcript levels of four JmjC genes, namely Jarid1b, Jmjd2d, Fbxl10 and 
Jmjd1c, were notably increased in the LTR-HSC-enriched fractions relative to total bone 
marrow cells (Fig. 1B). In contrast, Jhdm1d, Hspbap1 and Hairless transcript levels were 
notably higher in more mature cells. Genes expressed higher in the LTR-HSC enriched 
population e.g. Jarid1b, Jmjd2d, Fbxl10 and Jmjd1c were assigned a HSC expression score 
of one, while genes that were higher expressed in mature cells were attributed negative scores 
(Fig. 1B, lower panel). Increased expression in LTR-HSCs implied a HSC biological role, 
and these candidates were prioritized in the functional studies.   
 
Functional in vivo RNAi-based primary screen 
The shRNA based screen tested 23 of the 27 known JmjC mouse genes (Fig. 1C) for their 
potential functional role in HSC biology. shRNA Luciferase (shLuc) was used as a negative 
control, while shRNA Moz (shMoz) and Nup98Hoxa10-homeodomain (NA10hd) 
overexpression were used as controls for the loss and gain of HSC activity, respectively (data 
not shown for NA10hd, and31,32). HDM-directed shRNA sequences (n=112, Table S5) were 
subcloned into a LMP retroviral vector and assessed for their ability to modulate 
HSC/progenitor activity in vivo as previously reported 25 (summarized in Fig. 1D). The 
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biological impact of each shRNA was evaluated by serial sampling of peripheral blood from 
transplanted mice at early (3-4 weeks) and late (16-20 weeks) time points.  
To prioritize candidates for validation and downstream functional studies, a “selection 
threshold scoring system (STS),” weighted for HSC-enriched genes, was established (Fig. 2A 
and Table S3). HSC activity was determined by the long-term blood engraftment potential of 
the transduced donor cells (CD45.1+GFP+ cells) based on their contribution to blood 
leucocytes, calculated as a proportion of the total donor (CD45.1+) population, which 
comprises both transduced and non-transduced cells (%blood GFP= CD45.1+GFP+ cells/total 
CD45.1+ cells).  The percentage of blood reconstitution of the transduced cells was then 
compared to the respective gene transfer (GT) level on the day of transplantation (day0), and 
this ratio (Fig.2B, y-axis) used to document an increased (ratio>0.8072) or decreased 
(ratio<0.2751) contribution to the donor graft (HSC activity score). This ratio was used as GT 
levels for the hairpins presented in Fig.2B ranged from 20-80%, with an overall average of 
49% as previously reported25 (see also Table S4 for complete data), and thus transduced cell 
expansion or attrition could be measured. Overall, six hits were identified: Jmjd2a, Jhdm1f 
and Jmjd1b (STS of 2); Jarid1a, Jarid1b and Hif1an (STS of 3). Four of these genes; namely 
Jarid1a, Jarid1b, Jmjd2a, Hif1an, were identified as potential negative regulators of HSC 
activity (Fig. 2B, green shaded areas), while Jhdm1f and Jmjd1b (Fig. 2B, red area), as 
putative positive regulators. 
 
JmjC HDM knockdown validation experiments  
Hit validation was further restricted to proven JmjC domain containing histone demethylases 
(HIF1AN demethylase excluded as it targets HIF1α) and for technical considerations 
validation of potential positive regulators was limited to Jhdm1f. The increased hematopoietic 
reconstitution levels observed with shRNA mediated knockdown of the three remaining hits; 
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namely Jarid1a, Jarid1b, Jmjd2a (Fig.2B) prompted us to examine how the transduced HSCs 
would behave in vitro, where control HSCs normally exhaust rapidly26. Validation 
experiments were performed (Fig. 3A) and a gain-of-function phenotype for Jarid1a or 
Jmjd2a could not be confirmed upon shRNA transduction and prolonged in vitro culture 
(data not shown). Conversely, reducing Jarid1b levels in HSC populations by multiple 
shRNA moieties (shJarid1b 2, 3 and 4) clearly conferred an in vivo competitive advantage to 
freshly transduced cells compared to shLuc controls (Fig. 3B, left panel: n=3 different 
shRNAs to Jarid1b, day 0 transplanted cells). As higher GT rates were achieved in the 
validation experiments (>80%), blood reconstitution levels were measured as CD45.1+GFP+ 
cell percentages. The positive impact of shJarid1b on HSC activity was even more noticeable 
for cells transplanted after one week of in vitro culture (Fig. 3B, middle and right panels, 
cells transplanted after 7-day culture) to better detect HSC gain-of-function activity, as our 
previous studies demonstrated 26. Proportions of shJarid1b-transduced cells (GFP+) in 
peripheral blood remained well above those determined for shLuc controls for up to 10 
months (Fig. 3B). Knockdown of shJarid1b was determined for freshly transduced cells, and 
a >40% decrease in expression observed for shJarid1b 2, 3 and 4 (Fig. 3C).  Decreased HSC 
activity relative to control cells was confirmed with multiple shRNA constructs against 
Jhdm1f (n=5), Fig. 3D,E. All five shRNAs against Jhdm1f had knockdown efficiencies >40% 
(Fig. 3F). Validation experiments thus uncovered one negative (Jarid1b) and one positive 
(Jhdm1f) regulator of HSC activity. Further in vitro studies of shJhdm1f-transduced cells 
detected no significant change in proliferation or clonogenic progenitor activity of nucleated 
cells (Figure S1) indicating a distinct role for Jhdm1f in HSC repopulation ability.  The 
striking impact of Jarid1b knockdown on blood reconstitution oriented research towards 
Jarid1b function. 
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Jarid1b knockdown decreases hematopoietic cell differentiation in vitro 
Sh2- or sh3Jarid1b-transduced primitive hematopoietic cell populations had a ~1.5-2-fold 
proliferative advantage in vitro compared to shLuc controls, while Moz knockdown decreased 
expansion of the transduced cells (Fig. 4A, left panel).  The expanded shJarid1b-transduced 
populations comprised high proportions of morphologically immature cells (Fig. 4A, right 
panel), and lower percentages of differentiated (Gr1+) myeloid cells than shLuc controls (Fig. 
4B). Moreover, fractions of primitive (Gr1-) shJarid1b-transduced cells were comparable to 
that determined in response to NA10hd, a well characterized enhancer of in vitro 
HSC/progenitor cell expansion, while a marked elevation in differentiation was observed for 
shMoz loss-of-function control (Fig. 4B). During the 7-day culture period, the numbers of 
shJarid1b-transduced clonogenic progenitor cells (colony forming cell, CFC) increased ~3-
fold compared to shLuc and shMoz controls (Fig.4C). Jarid1b knockdown enhanced the 
proliferative capacity of individual CFCs compared to shMoz controls (Fig.4D), and 
promoted expansion of the highly proliferative granulocyte-macrophage progenitors (Fig. 
4E). Although the total CFC contents of shLuc and shMoz control cultures were comparable 
(Fig. 4C), and both cell populations differentiated into granulocytes and macrophages (Fig. 
4E), the antiproliferative effect of Moz knockdown was evident from the decrease in sizes of 
shMoz clones compared to shLuc controls (data not shown). 
 Q-RT-PCR assays involving selected candidates revealed a marked downregulation of 
differentiation associated genes Hairless (Hr) and Pu.1 in shJarid1b-cells compared to shMoz 
control (Fig. 4F). No major changes in expression levels of genes regulating senescence 
(Cdkn2a (p16) and Cdkn2d (p19)) or apoptosis (Bcl2, Mcl1) were detected in shJarid1b-cells, 
while modest increases in c-Myc and decreases in Mad1 levels resembled those determined 
for Hoxb4-overexpressing cells (data not shown, and33).  Moz knockdown was, however, 
clearly associated with upregulation of Hr, Cdkn2a and Cdkn2d expression.  This suggests 
 For personal use only. at SWETS INFORMATION SERVICES on August 21, 2013. bloodjournal.hematologylibrary.orgFrom 
13 
 
that Jarid1b knockdown promotes in vitro HSC/progenitor expansion by suppressing 
differentiation, while cells remained permissive to cell cycle re-entry. In contrast, reduced 
Moz expression enforced commitment to differentiation and senescence cell fate pathways. 
    
Jarid1b negatively regulates HSC self-renewal  
Transplant recipients of shJarid1b-cells had normal numbers of total bone marrow 
mononuclear cells (MNC), and no splenomegaly was observed (Fig. 5A, 1st and 2nd panels). 
Contributions of the transduced (GFP+) shLuc- and shJarid1b-cells to myeloid progenitor cell 
compartments were comparable (Fig. 5A, 3rd panel), but an ~8-10-fold increase in the 
frequencies of shJarid1b-multilineage progenitors (Colony Forming Unit-Granulocyte, 
Erythroid, Macrophage, Megakaryocyte, CFU-GEMM) compared to controls was observed 
(Fig. 5A, 4th panel).  This difference in immature progenitor cell content remained benign, 
and no hematological abnormalities could be detected during the 12 month observation 
period. Moreover, transplanted shJarid1b-cells generated normal proportions of myeloid 
(Mac1+/CD11b+), B-lymphoid (B220+/CD45R+) and T-lymphoid (CD4+, CD8+) progeny 
(Fig. 5B), suggesting that differentiation ability in vivo was not affected. 
To examine if Jarid1b knockdown favoured self-renewal divisions, leading to expansion of 
HSC populations, equal numbers of HSC-enriched (CD150+CD48-Lin-) cell populations were 
co-cultured with shLuc or shJarid1b retroviral producers.  HSC frequencies were determined 
in samples immediately after cell sorting and after a cumulative 12-day ex vivo culture period 
(Fig. 5C, top panel), using the CRU assay. CRU numbers in cell populations recovered from 
shLuc cultures (Fig. 5C, green bar) were comparable to those determined for the input cell 
population (Fig. 5C, red bar) suggesting no major loss or gain of HSCs during the in vitro 
incubation. In contrast, the CRU numbers in shJarid1b cultures increased 8- to 20-fold above 
shLuc control samples, or sorted cells prior to shJarid1b infection (Fig. 5C, blue bars), 
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suggesting that Jarid1b knockdown promoted the in vitro maintenance/expansion of long 
term-repopulating HSCs. Southern blot analyses of shJarid1b revealed a common proviral 
integration pattern between bone marrow (mostly myeloid, erythroid and B-), thymus (mostly 
T-) and spleen (B- and T-) cells of individual recipients (Fig. 5D) demonstrating 
multipotency and oligoclonal hematopoietic reconstitution of the expanded HSCs. 
 
Impact of Jarid1b knockdown on gene expression  
To examine downstream effects of Jarid1b knockdown, results of transcriptome next 
generation sequencing (RNAseq), Q-RT-PCR and ChIP-Chip assays were analyzed and 
compared to controls.  The similarity in HSC expansion observed between Jarid1b 
knockdown and Hox gene overexpression 31,33 and the recent report that JmjC members 
KDM6A (UTX) and KDM6B (JMJD3) are positive regulators of Hox gene expression 21 
prompted initial focus on the Hox family of transcription factors (Fig. 6A).   Both RNAseq 
and Q-RT-PCR assays revealed that Jarid1b knockdown induced a 2 to 5-fold increase in 5’ 
Hoxa gene (Hoxa5 to Hoxa11) expression levels compared to controls (Fig. 6A and Figure 
S2). RNAseq analysis identified upregulation of genes associated with key pathways such as 
erythroid differentiation, notch signalling and stem/progenitor cell function (Fig.6B and 
Figure S3), and downregulation of others involved in immune responses and differentiation 
(Fig. 6C and Figure S4). Several of the candidate downstream genes, including Hoxa7, Hes1, 
Hoxa10 and Hoxb2, were identified as potential direct epigenetic targets by enrichment of the 
associated H3K4me3 mark in 5’ loci as determined by ChIP-Chip assays (Fig. 6D and Figure 
S5).  Supporting this possibility, non-regulated genes e.g. Hoxa2 demonstrated no proximal 
promoter H3K4me3 enrichment following Jarid1b knockdown (Figure S5).  Jarid1b 
knockdown also correlated with downregulation of the previously reported putative JARID1 
target Cav134 (Table S7). 
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Study of epistasis between Jarid1b and Nup98Hoxa10-homeodomain 
To directly examine potential gene interaction of Jarid1b and Hoxa overexpression, 
HSC/progenitor cell populations were first transduced with NUP98Hoxa10-homeodomain 
(NA10hd) and the HSC-enriched populations (Sca1+CD43+ Gr1-F4/80-; Keith Humphries, 
personal communication) subsequently transduced with shJarid1b, shMoz, or control shLuc. 
The proportions of mature GR1+ F4/80+ cell fractions in each condition were evaluated as a 
measure of differentiation (Fig. 6E, upper panel). Results demonstrate that the combined 
effects of NA10hd overexpression and Jarid1b knockdown were additive, resulting in 
significant suppression of in vitro differentiation (p<0.0001; Student t-test) below the levels 
determined for control NA10hd+shLuc-cells (Fig. 6E, lower panel). In contrast, shMoz 
targeted knockdown overrode the maturation arrest imposed by NA10hd overexpression, and 
enforced differentiation above the levels determined for controls (Fig. 6E, lower panel).  
 
Together, the data presented support a role for Jarid1b in regulating key loci implicated in 
HSC cell fate and identify Jarid1b as a negative regulator of in vitro HSC expansion. 
 
DISCUSSION 
Following the established pipeline strategy from HSC isolation and infection to in vivo 
functional assessment of hematopoietic reconstitution, the presented RNAi screen highlighted 
Jarid1b as a negative and Jhmd1f as a positive modulator of HSC activity.  Due to defined 
inclusion criteria other HDMs should not be excluded as potential HSC modifiers. Akin to 
Hox gene overexpression, differentiation was restrained in shJarid1b-transduced HSC 
cultures as evidenced by more primitive cell morphology, reduced granulocytic maturation, 
and greater expansion of clonogenic progenitors relative to controls. After transplantation, ex 
vivo expanded HSCs were able to resume normal lympho-myeloid differentiation in recipient 
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mice, in the absence of lineage skewing or hematological abnormalities, for up to one year. 
Logarithmic ex vivo expansion of shJarid1b-transduced HSCs was demonstrated by CRU 
assays indicating that Jarid1b modulation influences stem cell fate decisions. Oligoclonal 
origin of the repopulating HSC pool and inherent multipotency of shJarid1b-transduced 
parental stem cells was shown by proviral insertion patterns in long-term recipient mice. 
Mechanistically, the competitive advantage conferred to shJarid1b-transduced HSCs could 
be attributed in part to the selective up-regulation of 5’ Hoxa genes. Segmental transcription 
of this chromosomal region is well documented 35 and particularly targeted by epigenetic 
regulators such as MLL or its derived fusion oncoproteins both in normal and leukemic stem 
cells 36. Interestingly, the 5’ Hoxa cluster is also targeted by the fusion oncoprotein NUP98-
JARID1A in a mouse model of myeloid leukemia37. 
 
In agreement with the proposed substrate specificity of JARID1B for H3K4me334, we noted 
enrichment for this epigenetic mark on 5’ Hoxa genes indicating that Jarid1b contributes to 
the negative regulation of Hoxa gene expression which when relieved following knockdown, 
leads in part to increased HSC activity. Enhancement of NA10hd-induced maturation arrest 
in the presence of reduced Jarid1b levels argues for regulation of additional cell fate 
determinants to account for the HSC phenotype seen. Comprehensive transcriptome analysis 
by RNAseq identified additional downstream genes, some of which are associated with key 
hematopoietic or stem cell associated pathways.  Recent reports further support a role for 
Jarid1b in transcriptional regulation of cell fate associated genes. PU.1 induction of 
transcription factor EGR2 was reported to recruit Jarid1b to the miR-17-92 promoter site, 
resulting in H3H4 demethylation and transcriptional silencing of the cluster required for 
monocyte maturation in a mouse model 19. Schmitz et al., recently reported that Jarid1b 
depletion prevents neuronal differentiation of ESCs by indirectly preventing H3K4 
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demethylation and silencing of pluripotency and germ cell-associated gene loci 20.  Similarly, 
H3K4me2/1 monoamine oxidase LSD1 was also deemed essential for proper hematopoietic 
progenitor differentiation38.         
We demonstrate that transcript levels of Jarid1b are increased in HSCs suggesting either a 
role in preventing unrestricted self-renewal divisions or in enabling downregulation of cell 
fate associated genes upon lineage commitment. Interestingly, 1q32 anomalies, which include 
Jarid1b, are common genetic mutations found in cells of chronic myeloid leukemia (CML) 
patients during disease progression characterized by a block in myeloid differentiation 39,40. 
This observation supports the hypothesis that low Jarid1b levels maintain stem cell fate, 
which combined with BCR-ABL induced proliferation, could result in development of overt 
leukemia. In our studies, transplant recipients of shJarid1b-transduced cells never developed 
leukemia. However, all Jarid1b hairpins tested achieved similar gene knockdown (≤50%), 
and more drastic outcomes following complete Jarid1b depletion cannot be ruled out. Two 
Jarid1b null alleles, one (exon 1 deletion) embryonic lethal41 the other (exon 6 deletion) no 
gross abnormalities,20 have recently been described. Precise elucidation of the role Jarid1b 
gene dosage plays in HSCs and leukemia development will thus likely require analyses of 
HSC-specific Jarid1b deletion. 
 
Overall, the data presented supports a cellular and developmental stage specific effect of 
Jarid1b levels in modulation of HSC cell fate. To sustain stem cell fate, integrated influences 
from various epigenetic effectors promote an active state of transcription at multipotency loci 
(Fig.7 upper panel). Activity of chromatin modifiers, including JARID1B, should culminate 
in maintenance of the H3K4me3 epigenetic mark on these loci, and exclusion of repressive 
marks, such as H3K9me3 or H3K27me3. Jhdm1f/PHF8 has recently been identified as a key 
regulator of ATRA response in acute promyelocytic leukemia cells43. Whether JHDM1F 
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activity influences the methylation status of H3K9 or normal HSC fate decisions remains to 
be explored. In contrast, removal of the active H3K4me3 epigenetic mark, potentially by 
JARID1B, could repress transcription of “stemness” genes and favor lineage commitment 
(Fig. 7, lower panel). Other JmjC candidates (e.g. Hif1an) may also be involved in this 
process, underscoring the importance of further characterization of these enzymes in the 
context of HSC regulation.  
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FIGURE LEGENDS 
Figure 1. JmjC gene expression in HSC/progenitor cell populations and selection for 
RNAi screen.  A) Transcript levels of histone demethylases (HDM) in HSC enriched cell 
populations. Results show ΔCT values determined by quantitative (Q) RT-PCR assays (with 
respect to endogenous Hprt expression levels, Ct~22) and represent average ± SEM of 5 
independently sorted HSC populations (bone marrow, n=3; E14.5 d.p.c. fetal liver, n=2). 
Frequencies of long term-repopulating HSCs in these populations are shown in Table S1. B) 
Comparison of HDM transcript levels detected in HSCs and total bone marrow cell 
populations. Relative transcript quantities (RQ) are shown in log2 scale, and represent the 
ΔCT (HSC)/ΔCT(bone marrow) ratio determined by quantitative RT-PCR assays (average ± 
SEM, n=3). An HSC expression score was implemented based on expression levels (ΔCT) 
and differential expression (RQ) of individual HDM, to rank gene candidates according to 
relative expression in HSC vs mature cells: gene not expressed in HSC, -2; less (<) expressed 
in HSC vs mature cells, -1; more (>) expressed in HSC, +1; equally expressed, 0.  C) List of 
the 23 HDM candidates tested in primary screen. HDMs sub-families sharing similarities 
outside the catalytic domain are denoted by different shading. Left column, the revised 
current terminology; central column, synonyms; right column, proposed substrate 
specificity10,42. Four HDM genes were excluded from the screen:  Jarid1d and Uty map to 
chromosome Y and are thus likely not required for regulation of HSC activity; Pla3g4b 
belongs to the cytosolic phospholipase A2 family; Jhdm1e knockdown could not be achieved 
by any hairpin in two independent experiments. D) Schema of shRNA retroviral vector 
backbone (top), and experimental outline (bottom) of the primary screen at the bottom. At 16 
week after transplantation, increase in the proportion of GFP+ peripheral blood leukocytes 
above their input levels reflects knockdown of a negative regulator of HSC activity (green 
box), and the inverse outcome denotes a positive HSC regulator (red box). 
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Figure 2. HDM hit identification. A)  The selection threshold score for genes was 
calculated from the expression score (Fig. 1B) and HSC activity score or biological score, 
(Fig. 2B). Biological score represents the number of shRNAs per HDM which modulate HSC 
activity in recipients above or below the 95% confidence interval range established for 
control shLuc cells (dotted blue lines in Fig. 2B). Selection threshold score of 2 and above 
identifies hits selected for validation experiments. B) Contributions of GFP+ (shRNA-
transduced) cells to peripheral blood reconstitution of recipients at 20 weeks after 
transplantation. Results are presented as proportions GFP+ cells within the transplant-derived 
(CD45.1+) peripheral blood cells and are normalized for the  gene transfer efficiency 
determined on the day of transplantation (day 0). Green shaded areas, suppressors of HSC 
activity; red shaded areas, enhancers of HSC activity. Raw data for gene transfer rates and 
blood reconstitution levels for all recipients are provided in Table S4. 
 
Figure 3. Validation assays for identified hits. A) Schema of experimental design. B) 
Long-term contribution of GFP+ (shLuc+, shJarid1b+, or NA10hd+) cells to peripheral blood 
reconstitution of recipients; gene transfer > 80% for all conditions. Left panel: recipients of 
day 0 cells; central and right panel, recipients of day 7 cells. NA10hd, cells engineered to 
overexpress NUP98Hoxa10-homeodomain fusion protein and green fluorescent protein 
(GFP). C) Evaluation of Jarid1b knockdown in GFP+ shJarid1b-transduced cells compared 
to shLuc controls. Results represent average ± SEM (n=4) RQ values determined for 6 
different hairpins. Bars with dashed lines correspond to shRNA constructs (sh5,6 and 1) that 
did not achieve significant (ie >30%) knockdown of Jarid1b in BM HSC. D)  Long-term 
contribution of GFP+ (shLuc+, or shMoz+, or shJhdm1f+) cells to peripheral blood 
reconstitution in recipients of day 0 cells. Each recipient received a ¼ of the transduced cell 
population, or twice the number of input cells transplanted for validation experiment shown 
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in Fig. 3A. E). Short-term (3 weeks) contribution of GFP+ (shLuc+ or shJhdm1f+-transduced) 
cells to peripheral blood reconstitution in recipients of day 0 cells. GT=99% for all 
conditions. Experiment (as in Fig. 4D) was repeated to include all hairpins against Jhdm1f. F) 
Evaluation of Jhmdm1f knockdown in GFP+ shJhdm1f-transduced cells compared to shLuc 
controls. Results represent average ± SEM (n=3). RQ values determined for 5 different 
hairpins. G) Summary of screen results. 
 
Figure 4. Jarid 1b knockdown decreases hematopoietic cell differentiation in vitro. A) 
Left panel: Jarid1b knockdown increases yields of mononuclear cells in cultures initiated 
with shJarid-transduced HSC/progenitor cell populations (mean ±SD, n=2). Right panel: 
Wright-stained cytospin preparations of cells on day 9 of culture, 40x magnification, white 
arrows indicate primitive cells. B) shJarid1b suppresses in vitro differentiation of 
HSC/progenitor cell populations. Proportions of Gr1+ cells on day 9 of culture were 
determined by flow cytometry. Each dot represents an independent culture. C) Jarid1b 
knockdown enhances in vitro expansion of myeloid colony forming cells (CFC). The increase 
in CFC numbers was calculated from MNC and CFC numbers determined on days 2 and 9 
(mean ± SD, n=4). D) Images of the predominant colony types. shJarid1b, colony forming 
unit granulocyte-macrophage (CFU-GM), high proliferative potential; shMoz, colony forming 
unit macrophage (CFU-M), low proliferation. Left panels, bright field; right panels, 
epifluorescence. E) Proportions of the highly proliferative CFU-GM in cultures of shRNA-
transduced cells (mean ± SD, n=4). F) Q-RT-PCR-based comparison of cell fate-associated 
transcript levels in day 7 (Fig. 3A) shJarid1b and shMoz-cells compared to shLuc controls.  
 
Figure 5. In vitro-expanded shJarid1b-HSC retain long-term in vivo multipotency. A) 
Analysis of hematopoietic tissues in recipients of day 7 cells (Fig. 3B) at 1 year after 
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transplantation. From left to right: first panel, spleen weight; second panel, the total numbers 
of bone marrow cells pooled from pelvis, femur and tibia; third panel, CFC frequency in the 
GFP+ bone marrow cell populations; fourth panel, proportions of GFP+ multilineage 
progenitors (Colony Forming Unit-Granulocyte, Erythrocyte, Monocyte, Megakaryocyte, 
CFU-GEMM). Dots in first plot represent the numbers of individual mice for which all the 
described parameters were analyzed. B) Contribution of day 7 (Fig. 3A) shJarid 1b (GFP+) 
cells to reconstitution of myeloid (Mac1+), B-lymphoid (B220+) and T-lymphoid lineage 
(CD4+, CD8+) at 1 year after transplantation. An example of typical reconstitution observed 
in all recipients (n>10) is shown. C) Jarid1b knockdown promotes the in vitro expansion of 
LTR-HSCs. Upper panel, experimental outline. Lower panel, CRU numbers in freshly sorted 
(i.e., input) and day 7 shRNA-transduced cell populations (mean ± SE). shJarid1b CRUs 
were determined in 2 independent experiments (see Table S6). D) Clonal analysis of proviral 
integrations in DNA isolated from hematopoietic tissues of mouse from shJarid1b cohort 
introduced in Fig. 5C. DNA was digested with EcoRI which cuts once within the provirus 
such that each DNA fragment recognized by the 32P-labelled Gfp probe represents a unique 
integration event. Mouse ID#, the total dose of transplanted cells, and the estimated number 
of transplanted CRU are shown on top. T, thymus; S, spleen; BM, bone marrow. 
 
Figure 6. Jarid1b knockdown modulates molecular mechanisms implicated in 
maintenance of stemness. A) Quantification of Hox gene transcripts in shJarid1b-cells and 
shLuc controls as assessed by RNA sequencing (RNAseq) analysis. For each Hox cluster (a 
and b) genes, FPKM (fragments per kilobase per million reads) expression values are shown 
for both conditions. Error bars indicate SD. RNA was isolated from HSC enriched cells in 
culture (4 days following retroviral infection), and only cultures with gene transfer rates 
>90% were selected. For each condition, two biological replicates were sequenced.  B) 
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Average FPKM and fold-change expression values of the 40 most upregulated (FPKM>1 for 
shJarid1b-cells) and C) downregulated (FPKM >1 for shLuc controls) genes from the 
RNAseq experiment described in Fig. 6A. Genes annotated to specific functions are specified 
by a cross mark in respective columns. Complete data for all differentially expressed genes 
(q-value < 0.05; all FPKM values included) shown in Table S7. D) Enrichment for H3K4me3 
marks (black peaks) at the Hoxa7 and Hes1 loci in shJarid1b cells. Chromatin 
immunoprecipitation was carried out using day 7 (Fig. 5C) shJarid1b or shLuc-cells. Total 
H3K4me3 levels are presented in Fig. S6. E) Top panel: Experimental strategy for generation 
of Nup98Hoxa10-homeodomain (NA10hd) plus shRNA overexpressing cells. Following 
puromycin selection, the Sca1+CD43- Gr1-F4/80- NA10hd-transduced cells were infected 
with shLuc-, shMoz-, and shJarid1b 1b-carrying retroviruses. Lower panel: Jarid1b 
knockdown suppresses differentiation of NA10hd overexpressing cells. Proportions of 
Gr1+F4/80+ (i.e. differentiated) cells in cultures were determined by flow cytometry on day 7 
after shRNA transduction. Each dot represents individual culture comprising the transduced 
progeny of 1,500 CD150+CD48-Lin- bone marrow cells. 1: Manual curation 2,3 : 3.4- and 3.7-
fold enrichment with false discovery rate of 4.6E-24 and 4.2E-11 in Gorilla bioinformatic 
tool. *Denotes high H3K4me3 densities, refer to Fig. 6D.  
Figure 7. Proposed model for JARID1B activity in modulation of HSC fate. Grey shaded 
area: JARID1B erases the tri-methyl marks of H3K4 at stemness loci and represses activity of 
multipotency genes. Pink area: Decrease in JARID1B activity shifts balance in favour of 
histone methylases, preserving the active H3K4me3 mark at stemness loci to sustain 
multipotency.   
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